Singapore, May 12 -- Taiwan-based Bora Pharmaceuticals announced that its Board of Directors has approved the acquisition of the GMP manufacturing operations, including the CDMO business, of MacroGenics, Inc, for total consideration of $122.5 million, subject to customary working capital adjustments, and a contingent consideration of up to $5 million based on future customer orders.

The transaction includes a biologics drug substance manufacturing facility located in Rockville, Maryland and an associated warehousing centre in Frederick, Maryland. Upon closing of the acquisition, the company will sign a long-term CDMO Service Agreement with MacroGenics.Following closing, Bora Group intends to leverage the Rockville Site in cooperation wit...